177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer

The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer

(2017) Anna Yordanova et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617

(2017) Hojjat Ahmadzadehfar et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma

(2017) Kambiz Rahbar et al.   NUKLEARMEDIZIN-NUCLEAR MEDICINE

Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer

(2016) Kambiz Rahbar et al.   CLINICAL NUCLEAR MEDICINE

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

(2016) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors

(2016) Martina Benešová et al.   JOURNAL OF MEDICINAL CHEMISTRY

Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis

(2016) K. Rahbar et al.   JOURNAL OF NUCLEAR MEDICINE

German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

(2016) Kambiz Rahbar et al.   JOURNAL OF NUCLEAR MEDICINE

PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617

(2016) C. Kratochwil et al.   JOURNAL OF NUCLEAR MEDICINE

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

(2016) R. P. Baum et al.   JOURNAL OF NUCLEAR MEDICINE

Radioligand therapy with 177 Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use

(2016) Hojjat Ahmadzadehfar et al.   NUCLEAR MEDICINE AND BIOLOGY

Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer

(2016) Hojjat Ahmadzadehfar et al.   Oncotarget

Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis

(2015) Klaus Brasso et al.   EUROPEAN UROLOGY

Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer

(2015) M. Bene ova et al.   JOURNAL OF NUCLEAR MEDICINE

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide

(2013) K. L. Noonan et al.   ANNALS OF ONCOLOGY

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

(2013) C. Parker et al.   NEW ENGLAND JOURNAL OF MEDICINE